Findings from a new study show significant overall survival benefit of Novartis’ ribociclib in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with visceral metastases.
The findings are from a subgroup analysis of the phase 3 MONALESSA-3 and MONALEESA-7 trials and were presented during the ASCO20 Virtual Scientific Program.
Learn more and read the full article from Drug Topics.
Integrating HCV screening with breast cancer programs enhances care
June 25th 2024A recent study from France demonstrates that incorporating hepatitis C virus screening into breast cancer programs significantly improves patient engagement and access to effective antiviral treatments among older women.
Read More